Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug

被引:48
作者
Chen, Yiyin [1 ,2 ,3 ]
Yang, Xiaomin [1 ,2 ,3 ]
Zhao, Lin [5 ]
Almasy, Laszlo [6 ]
Garamus, Vasil M. [4 ]
Willumeit, Regine [4 ]
Zou, Aihua [1 ,2 ,3 ]
机构
[1] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China
[2] E China Univ Sci & Technol, Shanghai Key Lab Funct Mat Chem, Shanghai 200237, Peoples R China
[3] E China Univ Sci & Technol, Inst Appl Chem, Shanghai 200237, Peoples R China
[4] Helmholtz Zentrum Geesthacht, Inst Mat Res, Ctr Mat & Coast Res, D-21502 Geesthacht, Germany
[5] Soochow Univ, Coll Med, Sch Radiat Med & Protect, Suzhou 215123, Peoples R China
[6] Wigner Res Ctr Phys, Inst Solid State Phys & Opt, H-1525 Budapest, Hungary
关键词
Nanostructured lipid carrier; Docetaxel; SANS; SAXS; Cytotoxicity; NANOPARTICLES SLN; PHASE-II; DELIVERY; DOCETAXEL; CANCER;
D O I
10.1016/j.colsurfa.2014.04.032
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The aim of this study was to prepare a stable nanostructured lipid carrier (NLC) with biocompatible lipids and surfactants (Pluronic F68 and Cremophor EL) by high-pressure homogenization (HPH). Surface tension measurements were used to choose the suitable ratio between Pluronic F68 and Cremophor EL. Hydrophobic anticancer drug docetaxel (DTX) was used as an active pharmaceutical ingredient (API). The mean particle size of docetaxel loaded nanostructured lipid carrier (DTX-NLC), as determined by dynamic light scattering (DLS), was between 120 nm and 250 nm during the storage period of 30 days, with the entrapment efficiency decreasing from (60.5 +/- 5.0)% to (55.3 +/- 4.5)%, while zeta potential was slightly changed from (-43.19 +/- 3.6) mV to (-40.12 +/- 4.3) mV. Transmission electron microscopy (TEM) showed that some of DTX-NLCs have elongated shape. Small angle neutron scattering (SANS) demonstrated that DTX-NLC in solution contained dense core with perfectly smooth surface, while blank NLC had dense core but rough surface. The blank NLC and DTX-NLC showed cubic crystalline structure according to small angle X-ray scattering (SAXS). Wide angle X-ray diffraction (XRD) showed that adding of DTX increased the crystallinity of the NLC. Cytotoxicity was studied by MTT assay against Hela cells. The data suggested that blank NLC was biocompatible with HeLa cells while the DTX-NLC was more cytotoxic than pure DTX at the same drug concentration. DTX-NLC could be taken up into the cells more than pure DTX, which could be attributed to the better solubility of DTX after loading into NLC. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:36 / 43
页数:8
相关论文
共 49 条
[11]   PHASE-II STUDY OF DOCETAXEL FOR ADVANCED OR METASTATIC PLATINUM-REFRACTORY NON-SMALL-CELL LUNG-CANCER [J].
FOSSELLA, FV ;
LEE, JS ;
SHIN, DM ;
CALAYAG, M ;
HUBER, M ;
PEREZSOLER, R ;
MURPHY, WK ;
LIPPMAN, S ;
BENNER, S ;
GLISSON, B ;
CHASEN, M ;
HONG, WK ;
RABER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :645-651
[12]   Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation [J].
Gelderblom, H ;
Verweij, J ;
Nooter, K ;
Sparreboom, A .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) :1590-1598
[13]   Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis [J].
Gupta, Madhu ;
Vyas, Suresh P. .
CHEMISTRY AND PHYSICS OF LIPIDS, 2012, 165 (04) :454-461
[14]   Nanoparticles for drug delivery in cancer treatment [J].
Haley, Barbara ;
Frenkel, Eugene .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) :57-64
[15]   Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles [J].
Hwang, Ho-Young ;
Kim, In-San ;
Kwon, Ick Chan ;
Kim, Yong-Hee .
JOURNAL OF CONTROLLED RELEASE, 2008, 128 (01) :23-31
[16]  
Janos S., 1998, JNCI-J NATL CANCER I, V90, P300
[17]   Lipid nanoparticles for parenteral delivery of actives [J].
Joshi, Medha D. ;
Mueller, Rainer H. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (02) :161-172
[18]   Phase II trials of docetaxel (Taxotere®) in advanced ovarian cancer -: an updated overview [J].
Kaye, SB ;
Piccart, M ;
Aapro, M ;
Francis, P ;
Kavanagh, J .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) :2167-2170
[19]   Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): Effects on size, physical stability and particle matrix structure [J].
Kovacevic, A. ;
Savic, S. ;
Vuleta, G. ;
Mueller, R. H. ;
Keck, C. M. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 406 (1-2) :163-172
[20]   Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers [J].
Kuo, Yung-Chih ;
Chung, Jui-Fang .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2011, 83 (02) :299-306